Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CorMedix Inc. - Common Stock (NQ:CRMD)

11.22 -0.49 (-4.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CorMedix Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news worth reading about on Wednesday! 
Via InvestorPlace
CorMedix (CRMD) Q3 2023 Earnings Call Transcript
CRMD earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
CorMedix's DefenCath Aims to Tackle Catheter-Related Blood Stream Infections: Analyst
RBC Capital Markets initiated coverage on CorMedix Inc (NASDAQ: CRMD) with an Outperform rating and a  
Via Benzinga
The Latest Analyst Ratings for Cormedix
Via Benzinga
CorMedix (CRMD) Q2 2023 Earnings Call Transcript
CRMD earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Why Shares of CorMedix Are Slumping Thursday
The company announced a stock sale and the sale of prefunded warrants. 
Via The Motley Fool
Analyst Ratings for Cormedix
Analysts have provided the following ratings for Cormedix (NASDAQ:CRMD) within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Are Bank Stocks WFC, JPM, BAC Up Today?
Banks stocks are heading higher on Thursday as investors react to the positive results of a stress test from the Federal Reserve. 
Via InvestorPlace
What 5 Analyst Ratings Have To Say About Cormedix
Via Benzinga
CorMedix (CRMD) Q1 2023 Earnings Call Transcript
CRMD earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Recap: Cormedix Q1 Earnings
Via Benzinga
Preview: Cormedix's Earnings
Via Benzinga
Why Franklin Covey Shares Are Trading Higher By 25%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Sigilon Therapeutics, Inc. (NASDAQ: SGTX) shares climbed 523.8% to $24.25 after Eli Lilly agreed to acquire the company for $14.92/share in cash. 
Via Benzinga
FREY Stock Price Prediction: Is Freyr Battery Really Worth $13?
Freyr Battery (FREY) stock is on the move Thursday with heavy trading following positive coverage from analysts at Morgan Stanley. 
Via InvestorPlace
Why Is Cormedix (CRMD) Stock Down 23% Today?
Cormedix (CRMD) stock is falling hard on Thursday with heavy trading after the company priced a public offering of its shares. 
Via InvestorPlace
Expert Ratings for Cormedix
Via Benzinga
Cormedix's Return On Capital Employed Overview
Via Benzinga
A Preview Of Cormedix's Earnings
Via Benzinga
Why Cormedix (CRMD) Stock Is Getting Hammered
CorMedix Inc. (NASDAQ: CRMD) shares are trading lower by 23.27% to $3.89 Thursday morning after the company priced its public offering of 7.5 million shares at $4 per share and pre-funded warrants to... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why CorMedix Are Trading Lower By 22%; Here Are 20 Stocks Moving Premarket
Gainers Eco Wave Power Global AB (NASDAQ: WAVE) shares surged 123% to $3.48 in pre-market trading after dropping over 8% on Wednesday. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting Thursday with a detailed look at all of the biggest pre-market stock movers worth keeping an eye on today! 
Via InvestorPlace
As CorMedix's DefenCath Moves Forward On Regulatory Path, Analyst Boosts Price Target
Tuesday, CorMedix Inc (NASDAQ: CRMD) resubmitted New Drug Application for DefenCath to the FDA, and the submission has been acknowledged as  
Via Benzinga
Citius Pharmaceuticals Approaches End Of Trial For Catheter-Related Bloodstream Infections – How Are Analysts Scoring Its Stock?
The late-stage biopharma Citius Pharmaceuticals Inc. (NASDAQ: CTXR) is approaching the conclusion of the phase 3 trial for its drug, Mino-Lok. 
Via Benzinga
7 Small-Cap Biotech Stocks with Massive Potential
Although small-cap biotech stocks present high risks, if they hit one out of the park, the rewards can be astronomical. 
Via InvestorPlace
7 Biotech Stocks With Huge Return Potential for Long-Term Investors
Although a wildly speculative sector, the low-cost, high-potential biotech stocks to buy and hold may deliver the goods for gamblers. 
Via InvestorPlace
Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow
A surge in oncology drug development, coupled with increased patient access and early diagnosis, has resulted in a massive increase in global spending on cancer treatments. Due to this, the global... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.